A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19

Imperial College London0 sites192 target enrollmentJune 4, 2020

Overview

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35043093/ (added 20/01/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36684396/ (added 24/01/2023) 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/36194628/ Sub-study results (added 09/07/2024)

Registry

who.int

Start Date

June 4, 2020

End Date

July 31, 2021

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

•1\. Healthy adults from the following age ranges:
•1\.1\. For the dose escalation and evaluation, aged 18\- 45 years on the day of screening
•1\.2\. For the expanded safety evaluation, aged 18\-75 years on the day of screening
•2\. At a similar risk of acquiring SARS\-CoV2 infection to the general population
•3\. Willing and able to provide written informed consent
•4\. If female and of childbearing potential and not sterilised, willing to use a highly effective method of contraception from screening until 18 weeks after the last injection
•5\. If male and not sterilised, willing to avoid impregnating female partners from screening until 18 weeks after last injection
•6\. Willing to avoid all other vaccines 4 weeks after the first injection through to 4 weeks after the second injection
•7\. Willing and able to comply with visit schedule, complete online diaries and provide samples
•8\. Willing to grant authorised persons access to his/her trial\-related medical record and GP records either directly or indirectly

•1\. Pregnant or lactating
•2\. Presence of active systemic disease or pre\-exisiting conditions that require investigation or a change to treatment that in the opinion of the investigator may compromise the volunteer’s safety, preclude vaccination or compromise interpretation of the immune response to vaccine
•3\. History of COVID\-19 infection
•4\. History of severe or multiple allergies to drugs or pharmaceutical agents
•5\. History of severe local or general reaction to vaccination defined as:
•5\.1\. Local: extensive, indurated redness and swelling involving most of the arm, not resolving within 72 hours
•5\.2\. General: fever \>\= 39\.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
•6\. Ever received an experimental vaccine against COVID\-19
•7\. Receipt of any immunosuppressive agents within 18 weeks of screening by any route other than topical
•8\. Detection of antibodies to hepatitis C